What Adverum Biotechnologies, Inc.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 3 |
| Sells | 0 | 4 |
| Total trades | 0 | 33 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 377,449 |
| Disposed | 0 | 5,973,272 |
| Net activity | +0 | −5,595,823 |
Common stock only — 15 reported trades in the last 12 months are in a security these totals do not cover.
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Graham Dawn | Director | Dec 09 | Tender Offer · U | −5,000 | — | — | 0 |
| Fischer Laurent | CEO, PRESIDENT AND DIRECTOR | Dec 09 | Tender Offer · U | −522,666 | — | — | 0 |
| Fischer Laurent | CEO, PRESIDENT AND DIRECTOR | Dec 09 | Grant / award · A | +500,000 | — | — | 522,666 |
| Fischer Laurent | CEO, PRESIDENT AND DIRECTOR | Dec 09 | Tender Offer · U | −25,000 | — | — | 0 |
| Fischer Laurent | CEO, PRESIDENT AND DIRECTOR | Dec 09 | Tender Offer · U | −351,513 | — | — | 0 |
| Fischer Laurent | CEO, PRESIDENT AND DIRECTOR | Dec 09 | Exercise / conversion · M | +150,000 | $4.20 | +$630K | 351,513 |
| Rubinstein Linda M | CHIEF FINANCIAL OFFICER | Dec 09 | Tender Offer · U | −42,000 | — | — | 0 |
| Rubinstein Linda M | CHIEF FINANCIAL OFFICER | Dec 09 | Grant / award · A | +42,000 | — | — | 42,000 |
| Rubinstein Linda M | CHIEF FINANCIAL OFFICER | Dec 09 | Tender Offer · U | −8,125 | — | — | 0 |
| Rubinstein Linda M | CHIEF FINANCIAL OFFICER | Dec 09 | Tender Offer · U | −61,150 | — | — | 0 |
| Rubinstein Linda M | CHIEF FINANCIAL OFFICER | Dec 09 | Exercise / conversion · M | +48,750 | $4.20 | +$205K | 61,150 |
| Machado Clarence Patrick | Director | Dec 09 | Tender Offer · U | −8,818 | — | — | 0 |
| Scopa James Paul | Director | Dec 09 | Tender Offer · U | −10,333 | — | — | 0 |
| Frazier Life Sciences Public Fund, L.p. | 10% owner | Dec 09 | Tender Offer · U | −4,288,949 | $3.56 | −$15.3M | 0 |
| Soparkar Peter | CHIEF OPERATING OFFICER | Dec 09 | Tender Offer · U | −157,333 | — | — | 0 |
| Soparkar Peter | CHIEF OPERATING OFFICER | Dec 09 | Grant / award · A | +150,000 | — | — | 157,333 |
| Soparkar Peter | CHIEF OPERATING OFFICER | Dec 09 | Tender Offer · U | −13,125 | — | — | 0 |
| Soparkar Peter | CHIEF OPERATING OFFICER | Dec 09 | Tender Offer · U | −80,189 | — | — | 0 |
| Lupher, Jr. Mark L. | Director | Dec 09 | Tender Offer · U | −13,000 | — | — | 0 |
| Ozden Rabia Gurses | Chief Medical Officer | Dec 09 | Tender Offer · U | −85,000 | — | — | 0 |
Loading...
